(Q34335917)

1 August 2017

title

Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies (English)

1 reference

1 August 2017

11

Eugenii A Rabiner

1 reference

1 August 2017

16

Maurizio Fava

1 reference

1 August 2017

Emiliangelo Ratti

1

1 reference

1 August 2017

Paolo Bettica

2

1 reference

1 August 2017

Robert Alexander

3

1 reference

1 August 2017

Graeme Archer

4

1 reference

1 August 2017

David Carpenter

5

1 reference

1 August 2017

Gary Evoniuk

6

1 reference

1 August 2017

Roberto Gomeni

7

1 reference

1 August 2017

Erica Lawson

8

1 reference

1 August 2017

Monica Lopez

9

1 reference

1 August 2017

Helen Millns

10

1 reference

1 August 2017

David Trist

12

1 reference

1 August 2017

Michael Trower

13

1 reference

1 August 2017

Stefano Zamuner

14

1 reference

1 August 2017

Ranga Krishnan

15

1 reference

1 August 2017

language of work or name

English

0 references

publication date

28 March 2013

1 reference

Journal of Psychopharmacology

1 August 2017

published in

1 reference

1 August 2017

volume

27

1 reference

1 August 2017

issue

5

1 reference

1 August 2017

page(s)

424-434

1 reference

Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Altered nociception, analgesia and aggression in mice lacking the receptor for substance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

An open trial of oral sildenafilin antidepressant-induced sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Depression and suicide attempt as risk factors for incident unprovoked seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Consensus nomenclature for in vivo imaging of reversibly binding radioligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an NK1-receptor antagonist in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts General Hospital Sexual Functioning Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Review of pharmacological treatment in mood disorders and future directions for drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Substance P is expressed in hippocampal principal neurons during status epilepticus and plays a critical role in the maintenance of status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Substance P causes seizures in neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Temazepam's efficacy in patients with sleep onset insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

Redefining affective disorders: relevance for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

A Structured Interview Guide for the Hamilton Depression Rating Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

A tachykinin NK1 receptor antagonist, CP-122,721-1, attenuates kainic acid-induced seizure activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

A pharmacokinetic PET study of NK₁ receptor occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113480990

21 January 2018

Identifiers

DOI

10.1177/0269881113480990

1 reference

1 August 2017

1 reference